Perrigo Company (PRGON) Stock Price & Analysis
PRGON Stock Chart & Stats
- Day’s Range
- MXN 296.00 - MXN 296.00
- 52-Week Range
- MXN 296.00 - MXN 557.52
- Previous Close
- MXN 557.52
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 41.15B
- Enterprise Value
- MXN 4.45B
- Total Cash (Recent Filing)
- MXN 399.70M
- Total Debt (Recent Filing)
- MXN 3.29B
- Price to Earnings (P/E)
- ―
- Beta
- 0.03
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- 9.6
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 15.09%
Bulls Say, Bears Say
Bulls Say
Market Share Gains
Perrigo is gaining share in both U.S. and European self-care markets despite category declines. This indicates competitive relevance, retailer acceptance, and product demand that can support more durable revenue performance once temporary category softness and inventory adjustments ease.
Improved Service Levels
Material service-level improvement strengthens Perrigo’s ability to meet retailer demand and protect important customer relationships. Better execution can support share retention, improve product availability, and make future innovation launches more effective across its private-label and branded channels.
Cash Generation And Deleveraging
Positive operating cash flow and asset-sale proceeds are providing capital to reduce borrowings and improve financial flexibility. Although leverage remains substantial, sustained cash generation combined with debt repayment could lower interest burden and expand management’s ability to fund strategic initiatives.
Bears Say
Persistent Revenue Declines
Broad-based sales contraction indicates that Perrigo’s near-term growth engine remains under pressure across its self-care portfolio. Continued softness, seasonal weakness, and retailer inventory reductions can reduce operating leverage and make it harder for innovation and distribution gains to translate into sustained revenue growth.
Margin And EPS Pressure
Significant gross-margin compression and a sizeable planned under-absorption headwind weaken earnings quality even if sales stabilize. Lower profitability reduces the cash available for reinvestment and debt reduction, while execution must improve enough to offset fixed-cost pressure from lower volumes.
Elevated Leverage
A substantial debt balance leaves Perrigo exposed to higher financing costs and limits flexibility while profitability is weak. Debt reduction is progressing, but leverage remains an important structural constraint that could compete with investment, shareholder returns, and operational recovery priorities.
PRGON FAQ
What was Perrigo Company’s price range in the past 12 months?
What is Perrigo Company’s market cap?
When is Perrigo Company’s upcoming earnings report date?
How were Perrigo Company’s earnings last quarter?
Is Perrigo Company overvalued?
Does Perrigo Company pay dividends?
What is Perrigo Company’s EPS estimate?
How many shares outstanding does Perrigo Company have?
What happened to Perrigo Company’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Perrigo Company?
What is the TipRanks Smart Score and how is it calculated?
Perrigo Company Stock Smart Score
Company Description
Perrigo Company
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Albert A. Manzone
- Employees
- 8,100
- Website
- www.perrigo.com
- Address
- The Sharp Building, Dublin, DU, D02 TY74, IE
Perrigo Company (PRGON) Earnings & Revenues
PRGON Company Deck
PRGON Earnings Call
Earnings Call SentimentNeutral
The call balanced clear operational progress and strategic actions against ongoing top-line and margin pressures. Positive indicators include market share gains, substantial service-level improvements, a recovering Infant Formula business (+23% sales, +$60M operating income), acceleration of a scalable innovation pipeline, targeted cost-savings ($80–$100M program) and the use of $359M divestiture proceeds to reduce debt. Offsetting these positives were a 3%+ decline in net sales, 250 basis points of gross margin compression, notable retailer destocking (≈1.8% headwind), specialty segment weakness and an expected ~$0.60 EPS headwind in 2026 from under-absorption. Management maintained full-year guidance and emphasized that results are weighted to a stronger second half, signaling cautious optimism but acknowledging remaining execution and demand risks.
View all MX:PRGON earnings summariesPRGON Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 0 | 14 |
| Technical Analysis | 4 | 0 | 2 |
| Moving Averages | 0 | 0 | 12 |
